Paracrine Action of Mesenchymal Stem Cells Revealed by Single Cell Gene Profiling in Infarcted Murine Hearts

Background Mesenchymal stem cells (MSCs) have been recently demonstrated as a promising stem cell type to rescue damaged myocardium after acute infarction. One of the most important mechanisms underlying their therapeutic effects is the secretion of paracrine factors. However, the expression profile of paracrine factors of MSCs in infarcted hearts, especially at single cell level, is poorly defined. Methods and Results We aimed to depict the transcriptional profile of paracrine factors secreted by MSCs in vivo, with particular interest in the comparison between normal and infarcted hearts. Bone marrow mesenchymal stem cells were isolated and injected into mice hearts immediately after infarction surgery. Bioluminescence imaging (BLI) indicated a proportion of cells still alive even up to 10 days post surgery. Paralleled with survived cells, cardiac function was significantly improved after MSC injection compared to that in PBS-injected mice, indicated by MRI and histology. Despite increased number of vessels in MSC-injected hearts, endothelial cells and cardiomyocytes transdifferentiation were not observed in infarcted hearts 5 days after infarction. Furthermore, laser capture microdissection (LCM) followed by high through-put real time PCR was employed in our study, uncovering that the injected MSCs, compared to local cardiomyocytes, displayed elevated levels of secreted factors. To further investigate the regulation of those factors, we performed single cell analysis to dissect the gene expression profile of MSCs at single cell level in infarcted and normal hearts, respectively. Consistent with the in vivo observation, a similar regulation pattern of those factors was detected in cultured MSCs under hypoxia. Conclusions Our study, for the first time, elucidated gene expression profiles, as well as regulation of paracrine factors, of MSCs at single cell level in vivo, indicating that paracrine factors from MSCs account for the improvement of cardiac function after infarction.

[1]  O. De Wever,et al.  Mesenchymal stem cell secreted platelet derived growth factor exerts a pro-migratory effect on resident Cardiac Atrial appendage Stem Cells. , 2014, Journal of molecular and cellular cardiology.

[2]  V. Jeevanantham,et al.  Adult Bone Marrow Cell Therapy Improves Survival and Induces Long-Term Improvement in Cardiac Parameters: A Systematic Review and Meta-Analysis , 2012, Circulation.

[3]  C. Ventura,et al.  Rosuvastatin elicits KDR-dependent vasculogenic response of human placental stem cells through PI3K/AKT pathway. , 2012, Pharmacological research.

[4]  Liming Wu,et al.  Enhanced therapeutic effects of mesenchymal stem cells on myocardial infarction by ischemic postconditioning through paracrine mechanisms in rats. , 2011, Journal of molecular and cellular cardiology.

[5]  J. Hare,et al.  Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. , 2011, Circulation research.

[6]  Gen Suzuki,et al.  Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair. , 2011, American journal of physiology. Heart and circulatory physiology.

[7]  P. Doevendans,et al.  Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. , 2011, Cardiovascular research.

[8]  J. Sweedler,et al.  Profiling metabolites and peptides in single cells , 2011, Nature Methods.

[9]  Peter A. Altman,et al.  Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy: Functional Recovery and Reverse Remodeling , 2011, Circulation research.

[10]  Peter A. Altman,et al.  Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and effi , 2011, American heart journal.

[11]  Jarrett Rosenberg,et al.  Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. , 2011, The Journal of clinical investigation.

[12]  M. Gnecchi,et al.  Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. , 2011, Journal of molecular and cellular cardiology.

[13]  Gen Suzuki,et al.  Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair. , 2010, American journal of physiology. Heart and circulatory physiology.

[14]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[15]  Xiaohong Wang,et al.  Hsp20‐Engineered Mesenchymal Stem Cells Are Resistant to Oxidative Stress via Enhanced Activation of Akt and Increased Secretion of Growth Factors , 2009, Stem cells.

[16]  J. Willerson,et al.  Combined Therapy With Simvastatin and Bone Marrow–Derived Mesenchymal Stem Cells Increases Benefits in Infarcted Swine Hearts , 2009, Arteriosclerosis, Thrombosis and Vascular Biology.

[17]  M. Zviman,et al.  Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. , 2009, European heart journal.

[18]  T. Doyle,et al.  Hepatocyte Growth Factor or Vascular Endothelial Growth Factor Gene Transfer Maximizes Mesenchymal Stem Cell–Based Myocardial Salvage After Acute Myocardial Infarction , 2009, Circulation.

[19]  Richard T. Lee,et al.  Cardiac Progenitor Cells and Biotinylated Insulin-Like Growth Factor-1 Nanofibers Improve Endogenous and Exogenous Myocardial Regeneration After Infarction , 2009, Circulation.

[20]  H. Haider,et al.  IGF-1–Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell Mobilization via Paracrine Activation of SDF-1α/CXCR4 Signaling to Promote Myocardial Repair , 2008, Circulation research.

[21]  M. Gnecchi,et al.  Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy , 2008, Circulation research.

[22]  N. Rosenthal,et al.  Interleukin-10 From Transplanted Bone Marrow Mononuclear Cells Contributes to Cardiac Protection After Myocardial Infarction , 2008, Circulation research.

[23]  K. Dou,et al.  Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. , 2008, European heart journal.

[24]  H. Ichikawa,et al.  Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. , 2008, Journal of molecular and cellular cardiology.

[25]  Ling Wei,et al.  Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. , 2008, The Journal of thoracic and cardiovascular surgery.

[26]  S. Kitamura,et al.  Effect of Hypoxia on Gene Expression of Bone Marrow‐Derived Mesenchymal Stem Cells and Mononuclear Cells , 2007, Stem cells.

[27]  M. Ashraf,et al.  In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. , 2007, Journal of molecular and cellular cardiology.

[28]  M. Matsuzaki,et al.  Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. , 2006, American journal of physiology. Heart and circulatory physiology.

[29]  M. Ashraf,et al.  Bone Marrow Stem Cells Prevent Left Ventricular Remodeling of Ischemic Heart Through Paracrine Signaling , 2006, Circulation research.

[30]  J. Ingwall,et al.  Evidence supporting paracrine hypothesis for Akt‐modified mesenchymal stem cell‐mediated cardiac protection and functional improvement , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  M. Pittenger,et al.  Mesenchymal stem cells and their potential as cardiac therapeutics. , 2004, Circulation research.

[32]  B. Fleischmann,et al.  Bone marrow–derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation , 2004, Nature Medicine.

[33]  M. Burnett,et al.  Local Delivery of Marrow-Derived Stromal Cells Augments Collateral Perfusion Through Paracrine Mechanisms , 2004, Circulation.

[34]  Winfried Brenner,et al.  Assessment of the Tissue Distribution of Transplanted Human Endothelial Progenitor Cells by Radioactive Labeling , 2003, Circulation.

[35]  A I Caplan,et al.  Cytokine expression by human marrow‐derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL‐1α , 1996, Journal of cellular physiology.